Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1957 ARTÍCULOS , VIENDO DEL 1906 AL 1920

A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease

Rosenberg PB, Amjad H, Burhanullah H, Nowrangi M, Vandrey R, Pierre MJ, Outen JD, Schultz M, Marano C, Agronin M, Wilkins JM, Harper D, Laffaye T, Reardon E, Turner K, Ozonsi R, Drury M, Nguyen A, Hasoğlu T, Cromwell J, Leoutsakos JM, Forester BP.

Am J Geriatr Psychiatry. 2026 Feb;34(2):167-179. doi: 10.1016/j.jagp.2025.10.011. Epub 2025 Nov 10.

Zinc transporter proteins in the retina as potential biomarkers for staging early Alzheimer's disease: Comparative analysis in human and mouse models

Mashkani SMH, Bishop D, Adlard PA, Mojtaba Golzan S.

Neurobiol Aging. 2026 Jan;157:26-35. doi: 10.1016/j.neurobiolaging.2025.09.010. Epub 2025 Oct 1.

Reconciling recommendations for ethical sharing of biomarker results with Alzheimer's disease research participants: A systematic review and qualitative synthesis

Webster H, Zelinsky M, Rico V, Martinez K, Sankary L.

J Alzheimers Dis. 2026 Mar;110(1):46-57. doi: 10.1177/13872877251392555. Epub 2025 Nov 5.

Neuropsychiatric signatures across the Alzheimer's disease continuum in Down syndrome and sporadic forms: A biomarker-driven comparison

Botella M, Estanga A, Ros N, Saldias J, Cañada M, García-Sebastián M, Larrea JÁ, Echeverria M, Garrido A, Altuna M.

J Alzheimers Dis. 2026 Feb;109(3):1508-1519. doi: 10.1177/13872877251407121. Epub 2025 Dec 30.

Association of neighborhood disadvantage with Alzheimer's disease pathology and the stability of blood-based biomarker performance

Myoraku A, Hausle I, Mila-Aloma M, Thropp P, Wang LA, Doraiswamy PM, Tosun D; Alzheimer’s Disease Neuroimaging Initiative*.

J Prev Alzheimers Dis. 2026 Feb;13(2):100445. doi: 10.1016/j.tjpad.2025.100445. Epub 2025 Nov 23.

Amyloid Clearance and Transient CSF Aβ40 Reduction in a Case of ARIA-E/H Following Lecanemab Treatment

Naeshiro Y, Kitani-Morii F, Kasai T, Tanaka E, Kobayashi F, Ohara T.

Intern Med. 2026 Apr 1;65(7):1056-1060. doi: 10.2169/internalmedicine.6070-25. Epub 2025 Aug 21.

Clinimetrics: Towards a diagnostic neuropsychology grounded in Alzheimer's disease

Ilardi CR.

J Neuropsychol. 2026 Mar;20(1):246-255. doi: 10.1111/jnp.70008. Epub 2025 Aug 13.

Identifying a combination of biomarkers to predict treatment response to nabilone for agitation in Alzheimer's disease - an exploratory post hoc analysis

Wang HJ, Ruthirakuhan M, Andreazza AC, Beroncal EL, Black SE, Gallagher D, Herrmann N, Kiss A, Verhoeff NPLG, Lanctôt KL.

Neurodegener Dis Manag. 2026 Apr-Jun;16(3):263-272. doi: 10.1080/17582024.2025.2587549. Epub 2025 Nov 11.

Potential beneficial effects of PD-1/PD-L1 blockade in Alzheimer's disease: a systematic review and meta-analysis of preclinical and clinical studies

Yoon J, Ha H, Lee HW, Kim S, Yu YM, Chun H.

Mol Psychiatry. 2026 Feb;31(2):1156-1166. doi: 10.1038/s41380-025-03413-2. Epub 2025 Dec 15.

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials

Abushakra S, Doraiswamy PM, Hey JA, Tosun D, Barkhof F, Barakos J, Petrella J, Kesslak JP, Power A, Sabbagh M, Porsteinsson A, Cohen S, Gauthier S, Ritchie C, Watson D, McSweeney E, Boada M, Liang E, Bracoud L, McLaine R, Flint S, Schaefer JF, Yu J, Bray M, Hendrix S, Dickson S, Durrant A, Albayrak A, Tolar M.

CNS Drugs. 2026 Feb;40(2):199-214. doi: 10.1007/s40263-025-01251-y. Epub 2025 Dec 1.

Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid-beta drugs in Alzheimer's disease: a Bayesian meta-analysis

Ren S, Singh J, Gsteiger S, Cogley C, Reed B, Abrams KR, Dawoud D, Owen RK, Tappenden P, Quinn TJ, Bujkiewicz S.

J Comp Eff Res. 2026 Jan;15(1):e250095. doi: 10.57264/cer-2025-0095. Epub 2025 Dec 2.

Exploring the gut-brain-microbiome axis in Alzheimer's disease: Integrating metagenomics, metabolomics, and artificial intelligence for next-generation biomarker discovery

Oso TA, Ahmed MM, Okesanya OJ, Adebayo UO, Obadeyi KB, Othman ZK, Lucero-Prisno DE 3rd.

J Alzheimers Dis. 2026 Feb;109(4):1542-1557. doi: 10.1177/13872877251407700. Epub 2025 Dec 29.

Alzheimer's disease diagnosis and treatment: From pathophysiological insights to therapeutic advances in the era of precision neurology (2025 review)

Kim M, Kwon H, Sohn S, Lee WJ, Cho K, Kim GW.

J Alzheimers Dis. 2026 Jan;109(1):17-33. doi: 10.1177/13872877251391820. Epub 2025 Oct 29.

Near-Infrared Fluorescent Probe for the Early Diagnosis of Alzheimer's Disease

Liu Y, Sun Y, Zhao P, Liu Z, Wang Y, Wang Y, Zhao R, Wang C, Wang S.

Med Res Rev. 2026 Jan;46(1):5-39. doi: 10.1002/med.70000. Epub 2025 Jul 28.

Blood biomarkers for diagnosis and differential diagnosis of Alzheimer's disease in real-world clinical populations: A systematic review

Suresh S, Maffei L, Bauermeister S, Raymont V.

J Alzheimers Dis. 2026 Feb;109(4):1574-1589. doi: 10.1177/13872877251408510. Epub 2025 Dec 29.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias